Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentapiperide SCHEMBL25997 | 0.80 | MEN1 (0.51) | CHRM3CHRM2CHRM4HRH1CACNA1C | |
| Mecloxamine SCHEMBL249953 | 0.73 | BCL2 (0.43) | CHRM3CHRM2CHRM4HRH1CACNA1C | |
| Mecloxamine SCHEMBL5705589 | 0.69 | MAPT (0.41) | KCNH2CYP3A4MEN1GMNNLMNA | |
| Pentapiperium SCHEMBL1222217 | 0.66 | CHRM3 (0.66) | CHRM3CHRM2CHRM4CHRM1MEN1 | |
| Pentapiperium SCHEMBL454024 | 0.65 | CHRM3 (0.64) | CHRM3CHRM2CHRM4CHRM1MEN1 | |
| SCHEMBL343231 | 0.64 | CYP2D6 (0.71) | CHRM3CHRM2CHRM4CHRM1OPRM1 | |
| SCHEMBL17294736 | 0.63 | CYP2D6 (0.68) | CHRM3CHRM2CHRM4CHRM1OPRM1 | |
| SCHEMBL17294776 | 0.63 | CYP2D6 (0.68) | CHRM3CHRM2CHRM4CHRM1OPRM1 | |
| SCHEMBL17294730 | 0.63 | CYP2D6 (0.68) | CHRM3CHRM2CHRM4CHRM1OPRM1 | |
| SCHEMBL5072788 | 0.62 | CHRM2 (0.70) | CHRM3CHRM2CHRM4HRH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011005352-A1 | SUSTAINED-RELEASE DRUG DELIVERY COMPOSITIONS AND METHODS | UPM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100092562-A1 | SUSTAINED-RELEASE DRUG DELIVERY COMPOSITIONS AND METHODS | UPM PHARMACEUTICALS, INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2008064163-A2 | POLYMER COATED DRUG-ION EXCHANGE RESINS AND METHODS | MORTON GROVE PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080118570-A1 | POLYMER COATED DRUG-ION EXCHANGE RESINS AND METHODS | WOCKHARDT EU OPERATIONS (SWISS) AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2004087052-A2 | OIL-CONTAINING, ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITION FOR IMPROVED DELIVERY OF A THERAPEUTIC AGENT | LIPOCINE, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20030235595-A1 | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent | LIPOCINE, INC. | 2003-12-25 | — | — | US | disclosed |
| US-5980882-A | A SOLID OR A GEL MEDICINE COMPRISING DEXTROMETHORPHAN, CODEINE, MORPHINE, HYDRCODONE, PSEUDOEPHEDRINE, OR PHENYLPROPANOLAMINE AND COMPLEXED WITH CHELATING AGENT SELECTED FROM EDTA OR A SALT OF EDTA; STORAGE STABILITY | MEDEVA PHARMACEUTICALS MANUFACTURING (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0911039-A2 | Drug-resin complexes stabilized by chelating agents | Medeva Pharmaceutical Manufacturing, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080118570-A1 | POLYMER COATED DRUG-ION EXCHANGE RESINS AND METHODS | NSF, SEM1, ABCB11 | CHRM3 3892/4885CHRM2 3286/4885CHRM4 3379/4885 |
| US-20030235595-A1 | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent | LIPA, LIPC, CETP | CHRM3 2884/4885CHRM2 2491/4885CHRM4 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.